Try our Advanced Search for more refined results
Slayback Pharma LLC v. Sumitomo Dainippon Pharma Co., Ltd.
Case Number:
Case Type:
IPR
Status:
Final Written Decision
Petitioner:
Slayback Pharma LLC
Patent Owner:
Sumitomo Dainippon Pharma Co., Ltd.
Tech Center:
1600
-
Filed: June 05, 2020 00:00
Coverage
-
January 21, 2022
Slayback Gets PTAB To Wipe Out Schizophrenia Treatment IP
The Patent Trial and Appeal Board has invalidated dozens of claims in a Sumitomo Dainippon Pharma patent for treating schizophrenia without certain side effects, finding that the claims were obvious.
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
- Search PTAB cases and full-text documents.
- Download filings with the U.S. Patent & Trademark Office’s Patent Trial & Appeal Board.
- Set up alerts on new cases, follow ongoing cases, track new decisions and so much more!
TRY LAW360 FREE FOR SEVEN DAYS
View the PTAB case documentsAlready a subscriber? Click here to login
-
January 21, 2022